ArticleActa anaesthesiologica Scandinavica2026
Levosimendan in Cardiac Arrest (LeiCA): Protocol for a Randomized, Double-Blind, Phase II Clinical Trial.
Article in Acta anaesthesiologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Levosimendan in Cardiac Arrest (LeiCA): Protocol for a Randomized, Double-Blind, Phase II Clinical Trial.Acta anaesthesiologica Scandinavica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDespite developments in advanced life support, outcomes after out-of-hospital cardiac arrest (OHCA) remain poor. Levosimendan, a calcium-sensitizing inodilator commonly used in heart failure, has shown beneficial effects in several experimental models and anecdotal clinical cases of cardiac arrest. The Levosimendan in Cardiac Arrest (LeiCA) pilot trial will evaluate levosimendan as an adjunct to advanced life support in refractory OHCA.
methodsThis will be an investigator-initiated, randomized, double-blind, placebo-controlled, single-center pilot trial. Patients aged 18-75 years with witnessed, nontraumatic, refractory OHCA in Stockholm County, Sweden, will be eligible for enrollment by a physician-staffed emergency medical service unit. Forty patients will be randomized in a 3:1 ratio to receive a single intravenous bolus of either levosimendan 2.5 mg (n = 30) or placebo (n = 10), administered during cardiopulmonary resuscitation via prefilled, masked syringes. Both groups will receive routine advanced life support and postresuscitation care as applicable. Included patients eligible for hospital transfer will be admitted to Karolinska University Hospital in Solna, Stockholm, Sweden. The primary endpoint is 30-day survival. Secondary endpoints include additional clinical outcome measures.
conclusionThe LeiCA pilot trial will investigate the effects of levosimendan as an adjunct to advanced life support for refractory OHCA. The results will inform the design of a definitive multicenter trial.
trial registrationISRCTN15862521; October 22, 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.